高级检索

托伐普坦抵抗的相关研究进展

,  ,  ,  ,  , 

上一篇

下一篇

文章导航 > 临床心血管病杂志 > 2022 > 38(2): 88-90
许家伟, 王云, 杨艳, 等. 托伐普坦抵抗的相关研究进展[J]. 临床心血管病杂志, 2022, 38(2): 88-90. doi: 10.13201/j.issn.1001-1439.2022.02.002
引用本文: 许家伟, 王云, 杨艳, 等. 托伐普坦抵抗的相关研究进展[J]. 临床心血管病杂志, 2022, 38(2): 88-90. doi: 10.13201/j.issn.1001-1439.2022.02.002
shu
XU Jiawei, WANG Yun, YANG Yan, et al. Research progress in the resistance of tolaptan[J]. J Clin Cardiol, 2022, 38(2): 88-90. doi: 10.13201/j.issn.1001-1439.2022.02.002
Citation: XU Jiawei, WANG Yun, YANG Yan, et al. Research progress in the resistance of tolaptan[J]. J Clin Cardiol, 2022, 38(2): 88-90. doi: 10.13201/j.issn.1001-1439.2022.02.002
shu

托伐普坦抵抗的相关研究进展

    • 南昌市第一医院心血管内科(南昌，330000)

详细信息

Research progress in the resistance of tolaptan

    • Department of Cardiology, Nanchang First Hospital, Nanchang, 330000, China

More Information

    摘要
  • 利尿剂广泛运用于心力衰竭、肝硬化腹水、肾脏疾病当中，能显著改善患者的症状及水肿体征，缩短住院天数，但长期使用利尿剂会导致利尿剂抵抗，增加患者的再次入院率及病死率。临床上当患者发生利尿剂抵抗时会替换或者联合使用托伐普坦，提高利尿剂的反应来增加尿量、减轻患者容量负荷，且效果显著。然而，随着托伐普坦在临床中的不断运用，一些患者利尿效果出现反应差，甚至是无应答的现象。目前国内外对这一现象的相关研究较少，本文旨在对托伐普坦抵抗的影响因素及机制作一综述。
    Diuretics are widely used in heart failure, liver cirrhosis, ascites, and kidney diseases. They can significantly improve the symptoms and signs of edema in patients and shorten the length of hospital stay. However, long-term use of diuretics can lead to diuretic resistance and increase the patient's readmission rate and fatality rate. Clinically, when patients develop diuretic resistance, tolvaptan could be replaced or combined to improve the diuretic response to increase urine output and reduce the patient's volume load, and the effect was significant. With the continuous use of tolvaptan in the clinic, the diuretic effect of some patients has been poorly responsive or even non-responsive. At present, there are few related studies on this phenomenon at home and abroad. The purpose of this article is to review the influent factors and mechanisms of tolvaptan resistance.
    • HTML全文
  • 加载中
    • 参考文献(23)
  • [1]

    Maybauer MO, Maybauer DM, Enkhbaatar P, et al. Physiology of the vasopressin receptors[J]. Best Pract Res Clin Anaesthesiol, 2008, 22(2): 253-263. doi: 10.1016/j.bpa.2008.03.003

    [2]

    Gheorghiade M, Orlandi C, Burnett JC, et al. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan(EVEREST)[J]. J Card Fail, 2005, 11(4): 260-269. doi: 10.1016/j.cardfail.2005.03.009

    [3]

    Matsue Y, Suzuki M, Nagahori W, et al. Clinical effectiveness of tolvaptan in patients with acute decompensated heart failure and renal failure: design and rationale of the AQUAMARINE study[J]. Cardiovasc Drugs Ther, 2014, 28(1): 73-77. doi: 10.1007/s10557-013-6491-8

    [4]

    Kimura K, Momose T, Hasegawa T, et al. Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure[J]. J Cardiol, 2016, 67(5): 399-405. doi: 10.1016/j.jjcc.2015.09.020

    [5]

    Cleland J G, Swedberg K, Follath F, et al. The EuroHeart Failure survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis[J]. Eur Heart J, 2003, 24(5): 442-463.

    [6]

    Komajda M, Hanon O, Hochadel M, et al. Management of octogenarians hospitalized for heart failure in Euro Heart Failure Survey I[J]. Eur Heart J, 2007, 28(11): 1310-1318. doi: 10.1093/eurheartj/ehl443

    [7]

    Mullens W, Damman K, Harjola VP, et al. The use of diuretics in heart failure with congestion-a position statement from the Heart Failure Association of the European Society of Cardiology[J]. Eur J Heart Fail, 2019, 21(2): 137-155. doi: 10.1002/ejhf.1369

    [8]

    Neuberg GW, Miller AB, O'Connor CM, et al. Diuretic resistance predicts mortality in patients with advanced heart failure[J]. Am Heart J, 2002, 144(1): 31-38. doi: 10.1067/mhj.2002.123144

    [9]

    Hiramine Y, Uojima H, Nakanishi H, et al. Response criteria of tolvaptan for the treatment of hepatic edema[J]. J Gastroenterol, 2018, 53(2): 258-268. doi: 10.1007/s00535-017-1366-6

    [10]

    Toda H, Nakamura K, Nakahama M, et al. Clinical characteristics of responders to treatment with tolvaptan in patients with acute decompensated heart failure: Importance of preserved kidney size[J]. J Cardiol, 2016, 67(2): 177-183. doi: 10.1016/j.jjcc.2015.04.017

    [11]

    Nakada Y, Okayama S, Nakano T, et al. Echocardiographic characteristics of patients with acute heart failure requiring tolvaptan: a retrospective study[J]. Cardiovasc Ultrasound, 2015, 13: 27. doi: 10.1186/s12947-015-0022-7

    [12]

    Shoaf SE, Bricmont P, Mallikaarjun S. Absolute bioavailability of tolvaptan and determination of minimally effective concentrations in healthy subjects[J]. Int J Clin Pharmacol Ther, 2012, 50(2): 150-156. doi: 10.5414/CP201621

    [13]

    Shoaf SE, Bricmont P, Mallikaarjun S. Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects[J]. Br J Clin Pharmacol, 2012, 73(4): 579-587. doi: 10.1111/j.1365-2125.2011.04114.x

    [14]

    Nakanishi H, Kurosaki M, Hosokawa T, et al. Urinary excretion of the water channel aquaporin 2 correlated with the pharmacological effect of tolvaptan in cirrhotic patients with ascites[J]. J Gastroenterol, 2016, 51(6): 620-627. doi: 10.1007/s00535-015-1143-3

    [15]

    Kawaratani H, Fukui H, Moriya K, et al. Predictive parameter of tolvaptan effectiveness in cirrhotic ascites[J]. Hepatol Res, 2017, 47(9): 854-861. doi: 10.1111/hepr.12826

    [16]

    Imamura T, Kinugawa K, Shiga T, et al. Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients--association between non-responders and chronic kidney disease[J]. Circ J, 2013, 77(2): 397-404. doi: 10.1253/circj.CJ-12-0971

    [17]

    Imamura T, Kinugawa K, Minatsuki S, et al. Urine osmolality estimated using urine urea nitrogen, sodium and creatinine can effectively predict response to tolvaptan in decompensated heart failure patients[J]. Circ J, 2013, 77(5): 1208-1213. doi: 10.1253/circj.CJ-12-1328

    [18]

    Moghazi S, Jones E, Schroepple J, et al. Correlation of renal histopathology with sonographic findings[J]. Kidney Int, 2005, 67(4): 1515-1520. doi: 10.1111/j.1523-1755.2005.00230.x

    [19]

    Nonin S, Iwata S, Ito A, et al. Right ventricular enlargement predicts responsiveness to tolvaptan in congestive heart failure patients with reduced ejection fraction[J]. Int J Cardiol Heart Vasc, 2018, 21: 69-73.

    [20]

    Kakeshita K, Koike T, Imamura T, et al. Expression of aquaporin-2 in the collecting duct and responses to tolvaptan[J]. CEN Case Rep, 2020.

    [21]

    Imamura T, Kinugawa K, Fujino T, et al. Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure[J]. Circ J, 2014, 78(9): 2240-2249. doi: 10.1253/circj.CJ-14-0244

    [22]

    何晓全, 高翔宇, 周力, 等. 托伐普坦联合重组人脑利钠肽在老年患者急性左心衰竭合并急性心肾综合征中的有效性[J]. 临床心血管病杂志, 2021, 37(12): 1137-1141. https://www.cnki.com.cn/Article/CJFDTOTAL-LCXB202112014.htm

    [23]

    沈祥礼, 李岚, 马骏, 等. 重组人脑利钠肽对利尿剂抵抗的临床观察[J]. 临床心血管病杂志, 2021, 37(3): 244-247. https://www.cnki.com.cn/Article/CJFDTOTAL-LCXB202103012.htm

    • 相关文章
  • 施引文献
  • 资源附件(0)
  • 加载中
计量
  • 文章访问数:  1632
  • PDF下载数:  532
  • 施引文献:  0
出版历程
收稿日期:  2021-07-13
修回日期:  2021-08-06
刊出日期:  2022-02-13

目录

    返回

    用微信扫描二维码

    分享至好友和朋友圈

    地址：

    邮政编码：

    电话：

    E-mail： lcxxgbzz@whuh.com

    {{newsColumn.name}}

    {{news.title}}

    版权所有 © 武汉协和医院杂志社 鄂ICP备 05004666-1 技术支持： 北京仁和汇智信息技术有限公司